Related Experiment Video

Updated: May 9, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target

Krishna P L Bhat1, Kenneth Aldape

  • 1Department of Pathology, and Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Cancer Discovery
|July 13, 2013
PubMed

Insights

Researchers found that diacylglycerol kinase alpha (DGKα) is a key player in cancer growth. Targeting DGKα effectively kills cancer cells and inhibits tumor growth in mice, showing its potential as a new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Diacylglycerol kinase alpha (DGKα) is an enzyme involved in lipid metabolism.
  • Oncogenic pathways, including mTOR, are frequently dysregulated in cancer.
  • Understanding upstream regulators of these pathways is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify novel molecular targets in cancer.
  • To investigate the role of diacylglycerol kinase alpha (DGKα) in oncogenic signaling.
  • To evaluate DGKα as a potential therapeutic target for cancer treatment.

Main Methods:

  • Enzyme activity assays to study diacylglycerol kinase alpha (DGKα) function.
  • Analysis of signaling pathways, including mTOR, in cancer cells.
  • In vivo studies using mouse models to assess tumor growth and toxicity.

Main Results:

  • Diacylglycerol kinase alpha (DGKα) was identified as a central node upstream of mTOR and other oncogenic pathways.
  • Targeting DGKα induced apoptosis in cancer cells.
  • Inhibition of DGKα led to tumor growth inhibition in mice.

Conclusions:

  • Diacylglycerol kinase alpha (DGKα) plays a critical role in cancer cell proliferation and survival.
  • DGKα represents a promising novel cancer-specific therapeutic target.
  • Targeting DGKα may offer a new strategy for cancer treatment with minimal toxicity.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...